Max Nisen, Columnist

Biogen is Still in Limbo

The prospects for its best-selling drug, pipeline and CEO search are cloudy.

October 26, 2016 at 6:38 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

Whoever takes over Biogen from outgoing CEO George Scangos is inheriting a decidedly mixed bag.

On the one hand, Biogen Inc. stock is outperforming its peers this year, and it jumped 3 percent on Wednesday after third-quarter earnings beat analyst expectations. On the other hand, the trajectory of its leading drug is uncertain, and its CEO search has no end in sight.